For research use only. Not for therapeutic Use.
DSM265（Cat No.:I006553）is a potent and selective dihydroorotate dehydrogenase (DHODH) inhibitor targeting the Plasmodium falciparum parasite, essential for malaria research. With its unique action on the parasite’s pyrimidine biosynthesis, DSM265 effectively disrupts parasite replication, making it valuable for antimalarial drug development. Its specificity for the DHODH enzyme in Plasmodium ensures minimal off-target effects on human DHODH, enhancing its therapeutic profile. DSM265’s extended half-life also supports its potential as a single-dose treatment option, offering a promising approach to reduce malaria transmission and improve patient compliance.
| Catalog Number | I006553 |
| CAS Number | 1282041-94-4 |
| Synonyms | DSM265; DSM-265; DSM 265; 1282041-94-4;2-(1,1-difluoroethyl)-5-methyl-N-(4-(pentafluoro-l6-sulfanyl)phenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine |
| Molecular Formula | C14H12F7N5S |
| Purity | ≥95% |
| Target | DHODH inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | 2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-lambda6-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine |
| InChI | InChI=1S/C14H12F7N5S/c1-8-7-11(26-13(22-8)24-12(25-26)14(2,15)16)23-9-3-5-10(6-4-9)27(17,18,19,20)21/h3-7,23H,1-2H3 |
| InChIKey | OIZSVTOIBNSVOS-UHFFFAOYSA-N |
| SMILES | CC1=NC2=NC(=NN2C(=C1)NC3=CC=C(C=C3)S(F)(F)(F)(F)F)C(C)(F)F |
| Reference | </br>1:DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Sulyok M, Rückle T, Roth A, Mürbeth RE, Chalon S, Kerr N, Samec SS, Gobeau N, Calle CL, Ibáñez J, Sulyok Z, Held J, Gebru T, Granados P, Brückner S, Nguetse C, Mengue J, Lalremruata A, Sim KL, Hoffman SL, Möhrle JJ, Kremsner PG, Mordmüller B.Lancet Infect Dis. 2017 Mar 28. pii: S1473-3099(17)30139-1. doi: 10.1016/S1473-3099(17)30139-1. [Epub ahead of print] PMID: 28363637 Free Article</br>2:Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. McCarthy JS, Lotharius J, Rückle T, Chalon S, Phillips MA, Elliott S, Sekuloski S, Griffin P, Ng CL, Fidock DA, Marquart L, Williams NS, Gobeau N, Bebrevska L, Rosario M, Marsh K, Möhrle JJ.Lancet Infect Dis. 2017 Mar 28. pii: S1473-3099(17)30171-8. doi: 10.1016/S1473-3099(17)30171-8. [Epub ahead of print] PMID: 28363636 Free Article</br>3:A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, Njoroge JW, El Mazouni F, Lao Y, Kokkonda S, Tomchick DR, Deng X, Laird T, Bhatia SN, March S, Ng CL, Fidock DA, Wittlin S, Lafuente-Monasterio M, Benito FJ, Alonso LM, Martinez MS, Jimenez-Diaz MB, Bazaga SF, Angulo-Barturen I, Haselden JN, Louttit J, Cui Y, Sridhar A, Zeeman AM, Kocken C, Sauerwein R, Dechering K, Avery VM, Duffy S, Delves M, Sinden R, Ruecker A, Wickham KS, Rochford R, Gahagen J, Iyer L, Riccio E, Mirsalis J, Bathhurst I, Rueckle T, Ding X, Campo B, Leroy D, Rogers MJ, Rathod PK, Burrows JN, Charman SA.Sci Transl Med. 2015 Jul 15;7(296):296ra111. doi: 10.1126/scitranslmed.aaa6645. PMID: 26180101 Free PMC Article |
